[1]陈非非,张璐莹,俞纯璐,等.DRG付费下创新医疗技术的额外支付机制研究 ——基于国际经验与启示[J].卫生经济研究,2023,40(8):28-32.
　CHEN Feifei,ZHANG Luying,YU Chunlu,et al.Study on Additional Payment Mechanism for Innovative Medical Technologies under DRG Payment ——Based on International Experience and Enlightenment[J].Journal Press of Health Economics Research,2023,40(8):28-32.
点击复制

DRG付费下创新医疗技术的额外支付机制研究
——基于国际经验与启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
40
期数:
2023年8期
页码:
28-32
栏目:
筹资与支付
出版日期:
2023-07-26

文章信息/Info

Title:
Study on Additional Payment Mechanism for Innovative Medical Technologies under DRG Payment
——Based on International Experience and Enlightenment
作者:
陈非非1; 张璐莹1; 俞纯璐1; 陈 星1; 陈 文1
1.复旦大学公共卫生学院，上海 200032
Author(s):
CHEN Feifei;  ZHANG Luying;  YU Chunlu;  CHEN Xing;  CHEN Wen
School of Public Health, Fudan University, Shanghai 200032, China
关键词:
DRG付费; 创新医疗技术; 额外支付; 国际经验
Keywords:
DRG payment;  innovative medical technologies;  additional payment;  international experience
分类号:
R19
文献标志码:
A
摘要:
DRG付费是我国医保支付方式改革的重点方向，然而可能对创新医疗技术的使用产生一定负面影响。对此，许多国家对创新医疗技术设立额外支付机制。本文对美国、德国、法国三个国家的实践进行分析，总结了对我国创新医疗技术额外支付机制的政策启示。
Abstract:
Diagnosis related groups(DRG) payment is one of key orientation in health security reform. It may have a dampening effect on the promotion of innovative medical technologies. Through literature research，this paper summarizes and sorts out the specific practices of typical countries in terms of inclusion criteria, application process, and payment standards for additional payment for innovative medical technologies, and proposes policy implications in terms of the additional payment establishment for innovative medical technologies in the context of China's national conditions.

参考文献/References:

[1] 国家医疗保障局.关于印发DRG/DIP 支付方式改革三年行动计划的通知[EB/OL].（2021-11-19）[2022-12-27].http://www.nhsa.gov. cn/art/2021/11/26/art_104_7413.html.
[2] Sorenson C,Drummond M,Torbica A,et al.The role of hospital payments in the adoption of new medical technologies:an international survey of current practice[J].Health Economics Policy and Law,2015,10(2):133-159.
[3] 郎婧婧，江芹，王珊，等.典型国家DRG分组的比较研究与启示[J].中国卫生经济，2017，36（4）：50-53.
[4] 彭颖，金春林，王贺男.美国DRG付费制度改革经验及启示[J].中国卫生经济，2018，37（7）： 93-96.
[5] Clyde A T,Bockstedt L,Farkas J A,et al.Experience with medicare's new technology add-on payment program[J].Health Affairs,2008,27(6):1632-1641.
[6] Anderson G,Steinberg E.To buy or not to buy-technology acquisition under prospective payment[J].New England Journal of Medicine,1984,311(3):182-185.
[7] 周宇，郑树忠，孙国桢.德国的DRG付费制度[J].中国卫生资源，2004（3）：139-141.
[8] 李菲.DRGs在医院医疗费用支付中的应用研究——基于英国、德国和美国的实证分析[J].卫生经济研究，2019，36（1）：32-37.
[9] Henschke C,B?umler M,Weid S,et al.Extrabudgetary ('NUB') payments:a gateway for introducing new medical devices into the German inpatient reimbursement system?[J]. Journal of Management & Marketing in Healthcare,2010,3(2):119-133.
[10] 何青，江芹，郎婧婧，等.典型国家和地区DRG实施过渡期经验探讨[J].中国卫生经济，2017，36（11）：93-96.
[11] Scheller-Kreinsen D,Quentin W,Busse R.DRG-based hospital payment systems and technological innovation in 12 European countries[J].Value in Health,2011,14(8):1166-1172.
[12] Rachet-Jacquet L,Toulemon L,Rochaix L.Hospital payment schemes and high-priced drugs: evidence from the French add-on list[J].Health Policy,2021,125(7):923-929.
[13] de L OFFRE DE SOINS DGOS D G,du PILOTAGE DE LA PERFORMANCE DES ACTEURS DE L OFFRE DE SOINS PF S,des SOINS PF B Q E S.Notice d'information relative à la procédure de demande d'inscription ou de radiation d'un produit ou d'une prestation sur la liste en sus[EB/OL].(2021-12-17)[2022-12-27].https://solidarites-sante.gouv.fr/soins-et-maladies/medicaments/professionnels-de-sante/autorisation-de-mise-sur-le-marche/la-liste-en-sus/article/notice-d-information#t7-Criteres-de-radiation-d-un-produit-ou-une-prestation-inscrit-sur-la-nbsp.
[14] CMS.New medical services and new technologies[EB/OL].(2022- 11-02)[2022-12-27].https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/ewtech.
[15] YVES DAUDIGNY C D V G.Médicaments innovants:consolider le modèle fran?ais d'accès précoce[EB/OL].(2018-06-13)[2022-12-27].http://www.senat.fr/rap/r17-569/r17-5697.html.
[16] Wilke M H,Rathmayer M.Reimbursement in endoscopy:how can new procedures be implemented?[J].Visceral Medicine,2016,32(1):29-35.
[17] InEK.Verfahrenseckpunkte[EB/OL].(2022-09-30)[2022-12-27].https://www.g-drg.de/neue-untersuchungs-und-behandlungsmethoden-nub/drg/verfahrenseckpunkte.
[18] 吴晶，董心月，赵博雅.美国DRG下高值创新医疗技术的支付政策及启示[J].中国医疗保险，2022（6）：118-124.
[19] de L OFFRE DE SOINS DGOS D G,du PILOTAGE DE LA PERFORMANCE DES ACTEURS DE L OFFRE DE SOINS PF S,de SANT? ET S?CURIT? DES SOINS PF B A A P.Procédure d’inscription et de radiation d’une spécialité pharmaceutique[EB/OL].(2022-07-18)[2022-12-27].https://solidarites-sante.gouv.fr/soins-et-maladies/medicaments/professionnels-de-sante/autorisation-de-mise-sur-le-marche/la-liste-en-sus/article/procedure-d-inscription-et-de-radiation-d-une-specialite-pharmaceutique.
[20] Medicare program;Hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and fiscal year 2014 rates;Quality reporting requirements for specific providers;Hospital conditions of participation;Payment policies related to patient status. Final rules[J].Fed Regist,2013,78(160):50495-51040.
[21] Hernandez J,Machacz S F,Robinson J C.US hospital payment adjustments for innovative technology lag behind those in Germany, France, and Japan[J].Health Affairs,2015,34(2):261-270.
[22] 李伟，任雨青，丁锦希，等.德国DRG医院偿付系统中创新产品支付模式分析[J].中国医院，2021，25（12）：40-42.
[23] Morey J R,Katana M,Li L,et al.Adoption and trends in the medicare new technology add-on payment program[J].Journal of General Internal Medicine,2021,36(7): 2174-2176.
[24] Vazquez S B, Miller Z R,Perrinjaquet M,et al.Funding trends for in-hospital drugs:German NU B analysis[J].Value in Health, 2019,22: S495.

相似文献/References:

[1]丛鹂萱,王海银,金春林.美国创新医疗技术支付经验及启示[J].卫生经济研究,2019,(07):10.
　CONG Li-xuan,WANG Hai-yin,JIN Chun-lin.American Innovative Medical Technology Payment Experience and Enlightenment[J].Journal Press of Health Economics Research,2019,(8):10.
[2]裘凯音,王 佳,王伟红,等.市级统筹背景下DRG付费的公平性研究[J].卫生经济研究,2021,38(12):33.
　QIU Kai-yin,WANG Jia,WANG Wei-hong,et al.Research on the Fairness of DRG Payment at the Municipal Level[J].Journal Press of Health Economics Research,2021,38(8):33.
[3]徐莹波,吴志伟.DRG付费下打造医保基金安全生态圈的思考[J].卫生经济研究,2021,38(12):54.
　XU Ying-bo,WU Zhi-wei.Thoughts on Creating a Security Ecosystem of Medical Insurance Funds under DRG Payment[J].Journal Press of Health Economics Research,2021,38(8):54.
[4]林 敏,夏 燕,朱 婷,等.DRG付费改革对医院运营效率的影响研究[J].卫生经济研究,2021,38(12):62.
　LIN Min,XIA Yan,ZHU Ting,et al.Research on the Influence of DRG Payment Reform on Hospital Operation Efficiency[J].Journal Press of Health Economics Research,2021,38(8):62.
[5]张 弘,丁 科,谢俊明,等.“疗效价值付费”下的中医优势病种DRG付费方案探索[J].卫生经济研究,2021,38(12):75.
　ZHANG Hong,DING Ke,XIE Jun-ming,et al.Exploration of DRG Payment Scheme for Dominant Diseases of Traditional Chinese Medicine under "Efficacy Value Payment"[J].Journal Press of Health Economics Research,2021,38(8):75.
[6]林振威,吴风琴,程 斌,等.DRG付费下医生异化行为监管的实践及思考[J].卫生经济研究,2024,41(11):36.
　LIN Zhenwei,WU Fengqin,CHENG Bin,et al.Practice and Reflection on the Supervision of Doctor Alienated Behaviors under DRG Payment[J].Journal Press of Health Economics Research,2024,41(8):36.

更新日期/Last Update: 2023-07-26